Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension in China

The Prevalence, Disease Course, Prognosis and Interaction of Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03185572

Enrollment

1708

Registered

2017-06-14

Start date

2017-06-15

Completion date

2020-12-31

Last updated

2017-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Pulmonary Hypertension

Brief summary

Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). It is reported that over half of COPD patients develop pulmonary hypertension. COPD and pulmonary hypertension may have pathological or genetics interactions so that patients having both disorders tend to have poor prognosis. Echocardiography is widely used to detect pulmonary hypertension, but it's not accurate enough. Therefore, high-quality data reflecting the prevalence, disease course and outcome of pulmonary hypertension in COPD is very limited in China. The aim of the study is to detect pulmonary hypertension with right heart catheterization, describe its outcome in Chinese COPD patients and explore the underlying interaction mechanism.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Stable chronic obstructive pulmonary disease (COPD) patients

Exclusion criteria

* Patients with other serious respiratory diseases * Patients with pulmonary hypertension other than group 3 * Patients with right heart hypertrophy or dysfunction not caused by chronic obstructive pulmonary diseases * Patients with limited life expectancy * Patients with history of tracheal intubation or stoke, acute coronary syndrome in 6 months * Psychopath or addict

Design outcomes

Primary

Measure	Time frame	Description
COPD exacerbations	3 years	total hospitalizations times due to COPD exacerbations

Secondary

Measure	Time frame	Description
modified British medical research council (mMRC) score	3 years	COPD symptom score
COPD Assessment Test (CAT) score	3 years	COPD symptom score
6 minutes walk distance	3 years	meters
transplant-free survival rate	3 years	transplant-free survival rate in %

Countries

China

Contacts

Primary ContactGuohua Zhen, MD

guohuazhen@hotmail.com13517277794

Outcome results